While conventional therapies may sometimes remain effective even with altered Bid signaling, Bid-dependent apoptotic signaling appears to be crucial for responses to novel immunotherapies, highlighting Bid as a key determinant of immunotherapy sensitivity in multiple myeloma. Here, BID is linked to plasma cell myeloma.